港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

派格生物医药-B

60.700

-2.550-4.03%

成交量：83.76万

成交额：5,355.15万

市值：234.30亿

市盈率：-71.89

高：72.750

开：72.700

低：55.050

收：63.250

52周最高：72.750

52周最低：8.680

股本：3.86亿

香港流通股本：2.79亿

量比：4.00

换手率：0.30%

股息：- -

股息率：- -

每股收益(LYR):-0.844

净资产收益率：-224.15%

总资产收益率：-61.30%

市净率：83.96

市盈率(LYR):-71.89

市销率: -5530.15

数据加载中...

总览公司新闻资讯公告

派格生物医药-B涨超8%破顶 PB-718最新临床数据亮眼 PB-119商业化在即

派格生物医药-B(02565):MASH治疗研发取得重大里程碑突破，彻底打开千亿估值增长天花板

异动解读 | 派格生物医药-B盘中大涨7.57%，PB-119上市注册申请获受理

异动解读 | 派格生物医药-B盘中大涨7.57%，PB-119上市注册申请获受理，国内商业化在即

港股异动 | 派格生物医药-B(02565)涨超7%再创新高 PB-119上市注册申请已获受理国内商业化即将落地

派格生物医药-B(02565)：邹醒龙已获委任为联席公司秘书，授权代表及法律程序代理人

派格生物医药-B(02565)发布中期业绩，研发开支2629.4万元已成功构建覆盖6款针对慢性疾病领域的在研药物管线矩阵

香港恒生指数收跌0.21%恒生科技指数跌0.67%。东方甄选尾盘高位跳水收盘跌超20%盘中一度涨23%；生物医药概念股持

派格生物医药－Ｂ(02565)股价下跌8.066%，现价港币$32.14

阿斯达克财经

港股异动 | 派格生物医药-B(02565)再涨超15%创上市新高 GLP-1板块热度升温公司内在价值有望加速释放

港股异动 | 港股减肥药迎爆点银诺医药-B(02591.HK)首挂暴涨引领派格生物医药-B(02565.HK)涨超40% 公司核心品种PB-119商业化在即

港股生物医药股盘初走强！派格生物医药-B暴涨逾30%创新高

老虎资讯综合

银诺医药-B(02591)暗盘暴涨270%引市场聚焦GLP-1赛道，派格生物医药-B(02565)价值洼地增长可期

港股异动 | 派格生物医药-B(02565)午后涨超15%破顶 PB-119用于治疗T2DM预计将于年内获NDA批准

港股生物医药概念股强势拉升，中慧生物-B、北海康成-B涨超30%

老虎资讯综合

派格生物医药-B08月08日获主力加仓89.9万元

派格生物医药-B08月06日获主力加仓128.0万元

派格生物医药-B07月28日获主力加仓30.7万元

派格生物医药-B07月24日获主力加仓198.1万元

派格生物上市不足半年破发30% 流血上市背后的资本绝境

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02565/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物医药-B","latestPrice":60.7,"timestamp":1763366895008,"preClose":63.25,"halted":0,"volume":837550,"delay":0,"floatShares":279164339,"shares":386000000,"eps":-0.8443406280365985,"marketStatus":"已收盘","change":-2.55,"latestTime":"11-17 16:08:15","open":72.7,"high":72.75,"low":55.05,"amount":53551500,"amplitude":0.279842,"askPrice":60.7,"askSize":6500,"bidPrice":60.05,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.6568922130924525,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":5,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":63.25,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":3.995945,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":279164339,"roa":"-61.30%","roe":"-224.15%","lyrEps":-0.844341,"volumeRatio":3.995945,"shares":386000000,"dividePrice":0,"high":72.75,"amplitude":0.279842,"preClose":63.25,"low":55.05,"week52Low":8.68,"pbRate":"83.96","psRate":"-5530.15","week52High":72.75,"institutionHeld":0,"latestPrice":60.7,"committee":-0.733333,"eps":-0.8443406280365985,"divideRate":0,"volume":837550,"delay":0,"ttmEps":-0.6568922130924525,"open":72.7,"prevYearClose":15.6,"prevWeekClose":63.25,"prevMonthClose":60.1,"prevQuarterClose":54.2,"fiveDayClose":53.4,"twentyDayClose":52.05,"sixtyDayClose":30.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[{"date":"2025-08-26","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0,"sell":0,"strongSell":1,"meanLabel":"STRONG SELL","meanPercent":1,"analysts":1,"updateTime":1755187200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2025-11-14","current":-96.473383,"percent":0,"low":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"high":-11.114373,"avg":-37.222505,"sd":22.07937,"marketCap":17657144441},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-15","current":-39.959751,"twenty":-19.179784,"median":-13.542645,"eighty":-11.515029,"marketCap":12350577024},{"date":"2025-08-22","current":-41.864246,"twenty":-19.284777,"median":-13.964282,"eighty":-11.779976,"marketCap":12898633879},{"date":"2025-08-29","current":-41.44792,"twenty":-21.432837,"median":-14.946806,"eighty":-11.968242,"marketCap":10033166343},{"date":"2025-09-05","current":-50.678037,"twenty":-39.039264,"median":-17.018603,"eighty":-12.06328,"marketCap":12255314482},{"date":"2025-09-12","current":-58.538001,"twenty":-40.749762,"median":-18.438762,"eighty":-12.114019,"marketCap":14181548421},{"date":"2025-09-19","current":-57.311117,"twenty":-43.720929,"median":-18.952908,"eighty":-12.216159,"marketCap":13874467648},{"date":"2025-09-26","current":-63.587749,"twenty":-49.33228,"median":-19.070122,"eighty":-12.366345,"marketCap":15354038645},{"date":"2025-10-03","current":-60.149194,"twenty":-54.575673,"median":-19.16943,"eighty":-12.428323,"marketCap":14558420278},{"date":"2025-10-10","current":-60.121463,"twenty":-57.957283,"median":-19.199848,"eighty":-12.49878,"marketCap":14530503844},{"date":"2025-10-17","current":-60.168303,"twenty":-59.756564,"median":-19.2984,"eighty":-12.738571,"marketCap":14530503844},{"date":"2025-10-24","current":-61.301982,"twenty":-60.143648,"median":-20.51103,"eighty":-12.741458,"marketCap":14809668183},{"date":"2025-10-31","current":-69.345185,"twenty":-60.159469,"median":-22.018639,"eighty":-12.743079,"marketCap":16777776773},{"date":"2025-11-07","current":-59.401661,"twenty":-60.392128,"median":-34.33922,"eighty":-12.780248,"marketCap":14363005241},{"date":"2025-11-14","current":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"marketCap":17657144441}],"updateTime":1763353808626},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2566667794","title":"派格生物医药-B涨超8%破顶 PB-718最新临床数据亮眼 PB-119商业化在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2566667794","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566667794?lang=zh_cn&edition=fundamental","pubTime":"2025-09-10 10:03","pubTimestamp":1757469825,"startTime":"0","endTime":"0","summary":"派格生物医药-B涨超8%，高见52.2港元创新高。截至发稿，涨8.23%，报51.95港元，成交额1217.4万港元。消息面上，近日，派格生物披露了PB-718的一项Ib/IIa期临床试验结果。研究显示，经剂量滴定后，1.6mg剂量的PB-718治疗18周可显著降低肝脏脂肪含量，较基线变化百分比均值为-57.14%，最大降幅达62%。公司此前指出，由于PB-119的NDA已获国家药监局受理，公司预期将于不久的将来在中国商业化PB-119。据悉，派格生物已成功构建覆盖6款针对慢性疾病领域的在研药物管线矩阵。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250910100635a71af53e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250910100635a71af53e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2564279643","title":"派格生物医药-B(02565):MASH治疗研发取得重大里程碑突破，彻底打开千亿估值增长天花板","url":"https://stock-news.laohu8.com/highlight/detail?id=2564279643","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564279643?lang=zh_cn&edition=fundamental","pubTime":"2025-09-04 16:59","pubTimestamp":1756976368,"startTime":"0","endTime":"0","summary":"前有银诺医药IPO上市暗盘暴涨270%，后有派格生物医药-B三个月股价累涨超4倍，均体现出市场投资者对这一热门赛道的追捧。派格生物或有机会成为首家千亿市值的港股创新减肥药龙头。在此背景下，近日司美格鲁肽成为继Rezdiffra之后第二款获FDA批准用于治疗MASH的药物，引发了全球业界和市场的广泛关注。而在港市，派格生物同样是投资者配置MASH治疗赛道的稀缺标的，其关键载体便是PB-718。近日，派格生物披露了PB-718的一项Ib/IIa期临床试验结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","161726","02565","399441"],"gpt_icon":0},{"id":"1127284816","title":"异动解读 | 派格生物医药-B盘中大涨7.57%，PB-119上市注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1127284816","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127284816?lang=zh_cn&edition=fundamental","pubTime":"2025-09-01 10:54","pubTimestamp":1756695265,"startTime":"0","endTime":"0","summary":"派格生物医药-B今日盘中大涨7.57%，股价一度触及38.66港元的上市新高。截至发稿时，该股报38.04港元，涨幅为5.84%，成交额达1889.28万港元，引发市场广泛关注。此次股价上涨主要源于公司核心产品PB-119的新药上市申请已获国家药品监督管理局受理。这一重要进展标志着派格生物医药即将在中国实现PB-119的商业化，大大提升了投资者对公司未来发展前景的信心。值得注意的是，派格生物医药近期公布的中期业绩显示，公司目前仍处于研发投入阶段。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"gpt_icon":0},{"id":"1171347433","title":"异动解读 | 派格生物医药-B盘中大涨7.57%，PB-119上市注册申请获受理，国内商业化在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1171347433","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171347433?lang=zh_cn&edition=fundamental","pubTime":"2025-09-01 10:54","pubTimestamp":1756695264,"startTime":"0","endTime":"0","summary":"港股上市公司派格生物医药-B今日盘中大涨7.57%，股价一度触及38.66港元的历史新高，引发市场广泛关注。消息面上，派格生物医药近期公布的中期业绩显示，公司核心产品PB-119的新药申请已获国家药品监督管理局受理。公司预计在不久的将来将在中国实现PB-119的商业化，这一重大进展激发了投资者的信心，推动股价大幅上涨。值得注意的是，派格生物医药已成功构建了覆盖6款针对慢性疾病领域的在研药物管线。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"gpt_icon":0},{"id":"2564862924","title":"港股异动 | 派格生物医药-B(02565)涨超7%再创新高 PB-119上市注册申请已获受理 国内商业化即将落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2564862924","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564862924?lang=zh_cn&edition=fundamental","pubTime":"2025-09-01 10:50","pubTimestamp":1756695051,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B涨超7%，高见38.66港元，再创上市新高。截至发稿，涨5.84%，报38.04港元，成交额1889.28万港元。消息面上，派格生物医药近日发布中期业绩，该集团取得其他净收入人民币17.8万元，研发开支2629.4万元，每股亏损0.25元。公司表示，由于PB-119的NDA已获国家药监局受理，公司预期将于不久的将来在中国商业化PB-119。于上市后，公司预期会产生作为上市公司经营的相关成本。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1339760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02565","BK4211","PB","399441","161726","BK1161"],"gpt_icon":0},{"id":"2562734886","title":"派格生物医药-B(02565)：邹醒龙已获委任为联席公司秘书，授权代表及法律程序代理人","url":"https://stock-news.laohu8.com/highlight/detail?id=2562734886","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562734886?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 21:26","pubTimestamp":1756214768,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B(02565)发布公告，陈婉梅女士(陈女士)已提呈辞任本公司联席公司秘书(联席公司秘书)、香港联合交易所有限公司(联交所)证券上市规则(上市规则)第3.05条项下的授权代表(授权代表)及根据上市规则第 19A.13(2)条及香港法例第622章公司条例第16部所规定代表本公司于香港接收法律程序文件及通知的代表(法律程序代理人)，自2025年8月26日起生效。董事会进一步宣布，陈女士辞任后，邹醒龙先生(邹先生)已获委任为联席公司秘书，授权代表及法律程序代理人，自2025年8月26日起生效。黄一峰先生(黄先生)将继续担任另一名联席公司秘书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1335692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161726","02565","399441","BK1161"],"gpt_icon":0},{"id":"2562731750","title":"派格生物医药-B(02565)发布中期业绩，研发开支2629.4万元 已成功构建覆盖6款针对慢性疾病领域的在研药物管线矩阵","url":"https://stock-news.laohu8.com/highlight/detail?id=2562731750","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562731750?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 21:19","pubTimestamp":1756214369,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布截至2025年6月30日止6个月中期业绩，该集团取得其他净收入人民币17.8万元，研发开支2629.4万元，每股亏损0.25元。截至本公告日期，我们在于美国及中国推进技术创新、产品管线及业务营运方面取得重大进展。截至本公告日期，派格生物已成功构建覆盖6款针对慢性疾病领域的在研药物管线矩阵。由于PB-119的NDA已获国家药监局受理，我们预期将于不久的将来在中国商业化PB-119。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1335683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02565","BK1161","161726","399441"],"gpt_icon":0},{"id":"2560716690","title":"香港恒生指数收跌0.21%恒生科技指数跌0.67%。东方甄选尾盘高位跳水收盘跌超20%盘中一度涨23%；生物医药概念股持","url":"https://stock-news.laohu8.com/highlight/detail?id=2560716690","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560716690?lang=zh_cn&edition=fundamental","pubTime":"2025-08-19 16:10","pubTimestamp":1755591001,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1bf930694ff6f897309c9b48a89cff5a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2148510915.USD","513600","BK0239","BK1095","MCHmain","HHImain","LU0405327494.USD","BK0183","LU1997245177.USD","01477","02565","02390","BK1161","BK4077","BK0188","HSTECH","BK0060","BK1228","LU2495084118.USD","LU0359201885.HKD","399441","ZH","HSI","BK1515","BK0196","BK1516","LU2488822045.USD","LU0359202008.SGD","LU1969619763.USD","01672","HSImain","161726","LU1023057109.AUD","BK4509","01276","LU0359201612.USD","LU2580892789.USD","BK1574","LU1064131003.USD","MHImain","BK1519","LU0405327148.USD","LU1064130708.USD","159271","BK1132","600276","BK1191","01797","02833"],"gpt_icon":0},{"id":"2560576071","title":"派格生物医药－Ｂ(02565)股价下跌8.066%，现价港币$32.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2560576071","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560576071?lang=zh_cn&edition=fundamental","pubTime":"2025-08-19 13:40","pubTimestamp":1755582000,"startTime":"0","endTime":"0","summary":"[下跌股]派格生物医药－Ｂ(02565) 股价在下午01:40比前收市价下跌8.066%，现股价为港币$32.14。至目前为止，今日最高价为$35.34，而最低价为$32.14。总成交量为73.46万股，总成交金额为港币$2.47千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2508191254/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","161726","399441","02565"],"gpt_icon":0},{"id":"2560971246","title":"港股异动 | 派格生物医药-B(02565)再涨超15%创上市新高 GLP-1板块热度升温 公司内在价值有望加速释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2560971246","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560971246?lang=zh_cn&edition=fundamental","pubTime":"2025-08-18 14:07","pubTimestamp":1755497239,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B再涨超15%，高见37港元再创上市新高。截至发稿，涨14.5%，报36.64港元，成交额2599.96万港元。消息面上，近日诺和诺德司美格鲁肽获批MASH新适应症，引发GLP-1板块热度。公开资料显示，派格生物医药是一家专注于自主研究及开发慢性病创新疗法的生物技术公司，旗下共有6款在研药物，其中有4条管线与GLP-1类药物相关，适应症几乎都是针对肥胖、超重、糖尿病等领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"cbf47a4577f9edc070eedd7d841a6ced","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399441","02565","161726","BK4590","GLP","BK1161","BK4144"],"gpt_icon":0},{"id":"2559995124","title":"港股异动 | 港股减肥药迎爆点 银诺医药-B(02591.HK)首挂暴涨引领 派格生物医药-B(02565.HK)涨超40% 公司核心品种PB-119商业化在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2559995124","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559995124?lang=zh_cn&edition=fundamental","pubTime":"2025-08-15 09:39","pubTimestamp":1755221971,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b596819316a65b7eebee6f2210b3d5a1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["161726","02565","07226","YANG","02591","PB","399441","BK4211","HSCEI","BK4614","BK1161"],"gpt_icon":0},{"id":"1106179730","title":"港股生物医药股盘初走强！派格生物医药-B暴涨逾30%创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1106179730","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106179730?lang=zh_cn&edition=fundamental","pubTime":"2025-08-15 09:39","pubTimestamp":1755221968,"startTime":"0","endTime":"0","summary":"8月15日，港股生物医药股盘初走强，$派格生物医药-B(02565)$暴涨逾30%，创上市以来新高；$歌礼制药-B(01672)$、$九源基因(02566)$涨超6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b596819316a65b7eebee6f2210b3d5a1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","YANG","01672","BK1574","BK1191","HSCEI","BK4614","01477","BK1161","HSTECH","BK1515","02565","07226"],"gpt_icon":0},{"id":"2559963122","title":"银诺医药-B(02591)暗盘暴涨270%引市场聚焦GLP-1赛道，派格生物医药-B(02565)价值洼地增长可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2559963122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559963122?lang=zh_cn&edition=fundamental","pubTime":"2025-08-14 23:19","pubTimestamp":1755184741,"startTime":"0","endTime":"0","summary":"GLP-1赛道方兴未艾，获市场高度关注智通财经APP观察到，近日专注于GLP-1类药物研发的银诺医药-BIPO上市，其暗盘暴涨超270%，市值超324亿港币，而这反映的正是资本市场对于GLP-1类药物赛道以及内分泌疾病治疗市场的关注。实际上，在当下港市GLP-1类药物赛道中并不乏优质标的，派格生物医药-B便是其中的稀缺价值标的。而GLP-1RA因其可带来多重获益，在国内外各大指南中地位逐步提升，目前已被列为T2DM患者的一线治疗药物，维培那肽便是其中之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2b827bbc3b346a324213f3d186e2feaf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1329859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","BK4144","BK1161","161726","BK4590","399441","GLP","02565"],"gpt_icon":1},{"id":"2559931265","title":"港股异动 | 派格生物医药-B(02565)午后涨超15%破顶 PB-119用于治疗T2DM预计将于年内获NDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2559931265","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559931265?lang=zh_cn&edition=fundamental","pubTime":"2025-08-14 13:37","pubTimestamp":1755149842,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B午后涨超15%，盘中高见24.14港元创上市新高。消息面上，据派格生物医药-B招股书显示，PB-119用于治疗T2DM预计将于2025年获NDA批准，并在中国进行商业化。与此同时，PB-119已启动用于治疗肥胖症的Ib/IIa期临床试验，2024年6月完成受试者招募工作。除了T2DM和肥胖症以外，派格生物表示，还将发掘PB-119在联合疗法方面的治疗潜力，进一步扩大适应症范围。预计随着后续相关药物获批，国内减肥药市场有望快速增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1329453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4211","02565","161726","399441","PB","BK1161"],"gpt_icon":0},{"id":"1187244558","title":"港股生物医药概念股强势拉升，中慧生物-B、北海康成-B涨超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187244558","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187244558?lang=zh_cn&edition=fundamental","pubTime":"2025-08-13 10:01","pubTimestamp":1755050488,"startTime":"0","endTime":"0","summary":"8月13日，港股生物医药概念股强势拉升，$中慧生物-B(02627)$、$北海康成-B(01228)$涨超30%，$派格生物医药-B(02565)$涨近9%，$荃信生物-B(02509)$涨超6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"eea96c2db952be4ad0141d428041d6b9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","01228","02565","BK1161","02509","09939"],"gpt_icon":0},{"id":"2557266325","title":"派格生物医药-B08月08日获主力加仓89.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557266325","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557266325?lang=zh_cn&edition=fundamental","pubTime":"2025-08-08 16:15","pubTimestamp":1754640945,"startTime":"0","endTime":"0","summary":"08月08日, 派格生物医药-B股价涨7.73%，报收16.45元，成交金额678.1万元，换手率0.15%，振幅8.71%，量比1.94。派格生物医药-B今日主力资金净流入89.9万元，连续5日净流入，上一交易日主力净流入140.6万元。该股近5个交易日上涨7.10%，主力资金累计净流入482.8万元，其中3个交易日为股价下跌时净流入；近20日主力资金累计净流入2049.4万元，其中净流入天数为17日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808174209a47cfac3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808174209a47cfac3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2557322292","title":"派格生物医药-B08月06日获主力加仓128.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557322292","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557322292?lang=zh_cn&edition=fundamental","pubTime":"2025-08-06 16:15","pubTimestamp":1754468107,"startTime":"0","endTime":"0","summary":"08月06日, 派格生物医药-B股价涨1.45%，报收15.37元，成交金额325.3万元，换手率0.08%，振幅2.44%，量比0.86。派格生物医药-B今日主力资金净流入128.0万元，连续3日净流入，上一交易日主力净流入62.5万元。该股近5个交易日上涨3.02%，主力资金累计净流入252.3万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入1907.4万元，其中净流入天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806165641a47856d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806165641a47856d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2554383772","title":"派格生物医药-B07月28日获主力加仓30.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554383772","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554383772?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 16:15","pubTimestamp":1753690523,"startTime":"0","endTime":"0","summary":"07月28日, 派格生物医药-B股价涨1.57%，报收15.54元，成交金额377.7万元，换手率0.09%，振幅2.75%，量比0.37。派格生物医药-B今日主力资金净流入30.7万元，上一交易日主力净流入79.0万元。该股近5个交易日上涨6.58%，主力资金累计净流入578.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1655.9万元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728164916a4675e1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728164916a4675e1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2553200537","title":"派格生物医药-B07月24日获主力加仓198.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553200537","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553200537?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 16:15","pubTimestamp":1753344945,"startTime":"0","endTime":"0","summary":"07月24日, 派格生物医药-B股价涨0.26%，报收15.48元，成交金额823.0万元，换手率0.19%，振幅2.07%，量比0.66。派格生物医药-B今日主力资金净流入198.1万元，上一交易日主力净流入160.6万元。该股近5个交易日上涨12.99%，主力资金累计净流入666.0万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1631.3万元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724165913a6bf5150&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724165913a6bf5150&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2553297203","title":"派格生物上市不足半年破发30% 流血上市背后的资本绝境","url":"https://stock-news.laohu8.com/highlight/detail?id=2553297203","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553297203?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 15:50","pubTimestamp":1753257017,"startTime":"0","endTime":"0","summary":"聚焦GLP-1赛道的创新药企派格生物在今年5月27日登陆港交所，首日即暴跌25.9%，一个月内股价蒸发43.2%，至今仍深陷破发30%的泥潭。当资本市场为GLP-1狂欢时，派格生物却上演了一场惊心动魄的“资本大逃杀”。牌桌上的生死赌局尽管艰难上市，派格生物仍深陷资本困局。当资本市场给予GLP-1概念股超高溢价时，派格生物11港元的股价与破发30%的K线图形成刺眼对比——市场在用脚投票质疑其商业化前景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072315505297b206c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072315505297b206c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02565"],"gpt_icon":1}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":82,"code":"91000000","status":"200"}]}}